|
US5916891A
(en)
*
|
1992-01-13 |
1999-06-29 |
Smithkline Beecham Corporation |
Pyrimidinyl imidazoles
|
|
CZ219597A3
(cs)
*
|
1995-01-12 |
1998-03-18 |
Smithkline Beecham Corporation |
Nové sloučeniny
|
|
US5739143A
(en)
*
|
1995-06-07 |
1998-04-14 |
Smithkline Beecham Corporation |
Imidazole compounds and compositions
|
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
|
IL118544A
(en)
|
1995-06-07 |
2001-08-08 |
Smithkline Beecham Corp |
History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
|
|
ZA9610687B
(en)
*
|
1995-12-22 |
1997-09-29 |
Smithkline Beecham Corp |
Novel synthesis.
|
|
AP9700912A0
(en)
*
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
|
PL187516B1
(pl)
*
|
1996-01-11 |
2004-07-30 |
Smithkline Beecham Corp |
Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
|
|
ZA97175B
(en)
*
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
|
US6046208A
(en)
*
|
1996-01-11 |
2000-04-04 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US6372741B1
(en)
*
|
1996-03-08 |
2002-04-16 |
Smithkline Beecham Corporation |
Use of CSAID™ compounds as inhibitors of angiogenesis
|
|
EP0889888A4
(en)
*
|
1996-03-25 |
2003-01-08 |
Smithkline Beecham Corp |
NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
|
|
EP0889887A4
(en)
*
|
1996-03-25 |
2003-06-11 |
Smithkline Beecham Corp |
TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES
|
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
|
AU5147598A
(en)
*
|
1996-10-17 |
1998-05-11 |
Smithkline Beecham Corporation |
Methods for reversibly inhibiting myelopoiesis in mammalian tissue
|
|
ZA9711092B
(en)
*
|
1996-12-11 |
1999-07-22 |
Smithkline Beecham Corp |
Novel compounds.
|
|
US6020357A
(en)
*
|
1996-12-23 |
2000-02-01 |
Dupont Pharmaceuticals Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
|
US6548512B1
(en)
|
1996-12-23 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
|
US5929076A
(en)
*
|
1997-01-10 |
1999-07-27 |
Smithkline Beecham Corporation |
Cycloalkyl substituted imidazoles
|
|
EP1019394A1
(en)
*
|
1997-05-22 |
2000-07-19 |
G.D. Searle & Co. |
PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
|
|
US6979686B1
(en)
|
2001-12-07 |
2005-12-27 |
Pharmacia Corporation |
Substituted pyrazoles as p38 kinase inhibitors
|
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
|
AU7966198A
(en)
|
1997-06-13 |
1998-12-30 |
Smithkline Beecham Corporation |
Novel pyrazole and pyrazoline substituted compounds
|
|
EP0994870A4
(en)
|
1997-06-19 |
2002-10-23 |
Smithkline Beecham |
NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
|
|
US6339099B1
(en)
|
1997-06-20 |
2002-01-15 |
Dupont Pharmaceuticals Company |
Guanidine mimics as factor Xa inhibitors
|
|
US6251914B1
(en)
|
1997-07-02 |
2001-06-26 |
Smithkline Beecham Corporation |
Cycloalkyl substituted imidazoles
|
|
US6489325B1
(en)
|
1998-07-01 |
2002-12-03 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US6562832B1
(en)
|
1997-07-02 |
2003-05-13 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
AR016294A1
(es)
*
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
|
CA2306077A1
(en)
|
1997-10-08 |
1999-04-15 |
Smithkline Beecham Corporation |
Novel cycloalkenyl substituted compounds
|
|
EP1021173A1
(en)
*
|
1997-10-10 |
2000-07-26 |
Imperial College Innovations Limited |
Use of csaid?tm compounds for the management of uterine contractions
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
CA2310046A1
(en)
*
|
1997-11-14 |
1999-05-27 |
Sankyo Company Limited |
Pyridylpyrrole derivatives
|
|
AU1924699A
(en)
|
1997-12-19 |
1999-07-12 |
Smithkline Beecham Corporation |
Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
|
|
US7517880B2
(en)
*
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
US6130235A
(en)
*
|
1998-05-22 |
2000-10-10 |
Scios Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
JP2002516322A
(ja)
|
1998-05-22 |
2002-06-04 |
スミスクライン・ビーチャム・コーポレイション |
新規2−アルキル置換イミダゾール化合物
|
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
US6207687B1
(en)
*
|
1998-07-31 |
2001-03-27 |
Merck & Co., Inc. |
Substituted imidazoles having cytokine inhibitory activity
|
|
CA2341370A1
(en)
*
|
1998-08-20 |
2000-03-02 |
Smithkline Beecham Corporation |
Novel substituted triazole compounds
|
|
MXPA01002173A
(es)
|
1998-08-28 |
2003-07-14 |
Scios Inc |
Inhibidores de p38-alfa cinasa.
|
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
ATE342892T1
(de)
|
1998-08-29 |
2006-11-15 |
Astrazeneca Ab |
Pyrimidine verbindungen
|
|
US6632820B1
(en)
|
1998-08-29 |
2003-10-14 |
Astrazeneca Ab |
Pyrimidine compounds
|
|
AU6476599A
(en)
*
|
1998-11-03 |
2000-05-22 |
Novartis Ag |
Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
|
|
DE69914357T2
(de)
|
1998-11-04 |
2004-11-11 |
Smithkline Beecham Corp. |
Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
|
|
US6239279B1
(en)
|
1998-12-16 |
2001-05-29 |
Smithkline Beecham Corporation |
Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
|
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
CA2360934A1
(en)
|
1999-02-22 |
2000-08-31 |
Lin-Hua Zhang |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
JP2002539206A
(ja)
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
|
CO5170501A1
(es)
*
|
1999-04-14 |
2002-06-27 |
Novartis Ag |
AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
|
|
US6930101B1
(en)
|
1999-05-17 |
2005-08-16 |
The Regents Of The University Of California |
Thiazolopyrimidines useful as TNFα inhibitors
|
|
RU2278115C2
(ru)
*
|
1999-05-21 |
2006-06-20 |
Сайос Инк. |
ПРОИЗВОДНЫЕ ИНДОЛЬНОГО РЯДА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
|
|
IL146309A
(en)
|
1999-05-21 |
2008-03-20 |
Scios Inc |
Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
|
|
CA2374737C
(en)
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
US7122666B2
(en)
*
|
1999-07-21 |
2006-10-17 |
Sankyo Company, Limited |
Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
|
|
GB9919778D0
(en)
*
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
|
BR0014041A
(pt)
*
|
1999-09-17 |
2003-07-15 |
Smithkline Beecham Corp |
Utilização de csaids em infecção por rinovìrus
|
|
AU7922900A
(en)
*
|
1999-10-27 |
2001-05-08 |
Novartis Ag |
Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
|
|
ATE281439T1
(de)
|
1999-11-23 |
2004-11-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
|
EP1233950B1
(en)
|
1999-11-23 |
2005-10-05 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
|
|
JP2003514900A
(ja)
*
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
CSBP/p38キナーゼ阻害剤としての3,4−ジヒドロ−(1H)−キナゾリン−2−オン化合物
|
|
KR100793668B1
(ko)
*
|
1999-12-08 |
2008-01-10 |
파마시아 코포레이션 |
강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
PL357672A1
(en)
*
|
2000-03-30 |
2004-07-26 |
Shionogi & Co, Ltd. |
Novel process for producing fused imidazopyridine derivative and novel crystal form
|
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
JP2004503601A
(ja)
*
|
2000-07-13 |
2004-02-05 |
ファルマシア・コーポレーション |
眼のcox−2媒介疾患の処置及び予防におけるcox−2阻害剤の使用法
|
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
|
CN100525768C
(zh)
*
|
2000-10-23 |
2009-08-12 |
史密丝克莱恩比彻姆公司 |
新化合物
|
|
US6867300B2
(en)
*
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
DE60125980T2
(de)
|
2000-11-20 |
2007-10-25 |
Scios Inc., Sunnyvale |
P38kinase-inhibitoren vom piperidin/piperazin-typ
|
|
EP1341782A2
(en)
|
2000-11-20 |
2003-09-10 |
Scios Inc. |
Inhibitors of p38 kinase
|
|
EP1339708A2
(en)
*
|
2000-11-20 |
2003-09-03 |
Scios Inc. |
Indole-type inhibitors of p38 kinase
|
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
|
US7199124B2
(en)
*
|
2001-02-02 |
2007-04-03 |
Takeda Pharmaceutical Company Limited |
JNK inhibitor
|
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
|
AP2002002460A0
(en)
*
|
2001-03-09 |
2002-06-30 |
Pfizer Prod Inc |
Novel benzimidazole anti-inflammatory compounds.
|
|
PE20021017A1
(es)
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
|
WO2002094267A1
(en)
*
|
2001-05-24 |
2002-11-28 |
Sankyo Company, Limited |
Pharmaceutical composition for prevention or treatment of arthritis
|
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
|
US7076539B2
(en)
*
|
2001-07-30 |
2006-07-11 |
Hewlett-Packard Development Company, L.P. |
Network connectivity establishment at user log-in
|
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
|
GB0124938D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
ATE550332T1
(de)
*
|
2001-10-22 |
2012-04-15 |
Mitsubishi Tanabe Pharma Corp |
4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
|
|
US7727542B2
(en)
*
|
2001-10-25 |
2010-06-01 |
University Of Connecticut |
Bioactive materials, methods of making bioactive materials and method of use thereof
|
|
JP4518378B2
(ja)
*
|
2001-10-29 |
2010-08-04 |
ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング |
エネルギー恒常性および細胞小器官代謝の調節に関与するMnkキナーゼ相同性タンパク質
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
ATE375980T1
(de)
|
2002-02-12 |
2007-11-15 |
Smithkline Beecham Corp |
Nicotinamide und deren verwendung als p38 inhibitoren
|
|
EP1480973B1
(en)
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US7442697B2
(en)
|
2002-03-09 |
2008-10-28 |
Astrazeneca Ab |
4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
|
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
AR039241A1
(es)
*
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
|
PT1497019E
(pt)
|
2002-04-23 |
2015-09-10 |
Bristol Myers Squibb Co |
Compostos de pirrolotriazina anilina úteis como inibidores de quinase
|
|
ES2278170T3
(es)
|
2002-07-09 |
2007-08-01 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2004014900A1
(en)
*
|
2002-08-09 |
2004-02-19 |
Eli Lilly And Company |
Benzimidazoles and benzothiazoles as inhibitors of map kinase
|
|
WO2004019873A2
(en)
|
2002-08-29 |
2004-03-11 |
Scios Inc. |
Methods of promoting osteogenesis
|
|
AU2003268464A1
(en)
|
2002-09-03 |
2004-03-29 |
Scios Inc. |
INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
|
|
UA80295C2
(en)
*
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
|
UA80296C2
(en)
*
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
|
AU2003279230A1
(en)
|
2002-10-09 |
2004-05-04 |
Scios Inc. |
AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
|
|
CL2004000234A1
(es)
*
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308466D0
(en)
*
|
2003-04-11 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
US7652044B2
(en)
*
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
PL2298743T3
(pl)
|
2003-06-26 |
2013-02-28 |
Novartis Ag |
Inhibitory kinaz P38 na bazie 5-członowych heterocykli
|
|
US7105467B2
(en)
*
|
2003-07-08 |
2006-09-12 |
Pharmacore, Inc. |
Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
EP1687284B1
(en)
*
|
2003-07-25 |
2008-10-29 |
Novartis AG |
p-38 KINASE INHIBITORS
|
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
WO2005030091A2
(en)
|
2003-09-25 |
2005-04-07 |
Scios Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
|
US7419978B2
(en)
*
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
|
US7183305B2
(en)
*
|
2003-11-11 |
2007-02-27 |
Allergan, Inc. |
Process for the synthesis of imidazoles
|
|
US7880017B2
(en)
*
|
2003-11-11 |
2011-02-01 |
Allergan, Inc. |
Process for the synthesis of imidazoles
|
|
US7105707B2
(en)
*
|
2003-12-17 |
2006-09-12 |
Pharmacore, Inc. |
Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
|
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
|
KR100793479B1
(ko)
*
|
2004-04-28 |
2008-01-14 |
다나베 미츠비시 세이야꾸 가부시키가이샤 |
염증성 질환을 치료하기 위한 p38 MAP- 키나제억제제로서의4-2-(시클로알킬아미노)피리딘-4-일-(페닐)-이미다졸린-2-온 유도체
|
|
TWI326282B
(en)
|
2004-04-28 |
2010-06-21 |
Mitsubishi Tanabe Pharma Corp |
Heterocyclic compound
|
|
EP2295426A1
(en)
*
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
US7504521B2
(en)
*
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
|
JP2006182763A
(ja)
*
|
2004-12-03 |
2006-07-13 |
Daiso Co Ltd |
α,β−不飽和エステルの製法
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
|
US20060178388A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
|
GB0504753D0
(en)
*
|
2005-03-08 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
|
US20080096905A1
(en)
*
|
2005-03-25 |
2008-04-24 |
Glaxo Group Limited |
Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
|
|
MY145343A
(en)
*
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
US20060235020A1
(en)
*
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
US7473784B2
(en)
*
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
|
DE102005048072A1
(de)
*
|
2005-09-24 |
2007-04-05 |
Bayer Cropscience Ag |
Thiazole als Fungizide
|
|
AR056556A1
(es)
|
2005-09-30 |
2007-10-10 |
Astrazeneca Ab |
Imidazo(1,2-a)piridina con actividad antiproliferacion celular
|
|
DE102006001161A1
(de)
*
|
2006-01-06 |
2007-07-12 |
Qiagen Gmbh |
Verfahren zum Nachweis von Cytosin-Methylierungen
|
|
KR20080107408A
(ko)
*
|
2006-03-07 |
2008-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
|
|
AU2007235876A1
(en)
|
2006-04-12 |
2007-10-18 |
Probiodrug Ag |
Enzyme inhibitors
|
|
EP2083816A2
(en)
*
|
2006-10-27 |
2009-08-05 |
Brystol-Myers Squibb Company |
Heterocyclic amide compounds useful as kinase inhibitors
|
|
US7943617B2
(en)
*
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
CN102131805A
(zh)
|
2008-06-20 |
2011-07-20 |
百时美施贵宝公司 |
用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
|
|
WO2009155389A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
|
WO2016149756A1
(en)
|
2015-03-23 |
2016-09-29 |
The University Of Melbourne |
Treatment of respiratory diseases
|
|
JP7788128B2
(ja)
*
|
2017-05-03 |
2025-12-18 |
ティアンリ バイオテック プロプライエタリ リミテッド |
呼吸器疾患の治療のための化合物
|
|
BR112020006677A2
(pt)
|
2017-10-05 |
2020-10-06 |
Fulcrum Therapeutics, Inc. |
uso de inibidores p38 para reduzir a expressão de dux4
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
JP7614646B2
(ja)
*
|
2018-11-07 |
2025-01-16 |
ティアンリ バイオテック プロプライエタリ リミテッド |
呼吸器疾患の処置のための化合物及び組成物
|
|
US12479816B2
(en)
|
2019-02-08 |
2025-11-25 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
20-HETE formation inhibitors
|
|
US11987572B2
(en)
*
|
2019-06-03 |
2024-05-21 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods of use thereof
|
|
IL305573A
(en)
|
2021-03-15 |
2023-10-01 |
Saul Yedgar |
HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
|